Gut

Article	Citations
Unusual history of ‘stitch’	1953
Response to McAlindon’s letter	1195
Innumerable nodules in all parts of the small intestine	454
Hepatocyte senescence in alcohol-associated hepatitis: epiphenomenon or disease-driving mechanism?	442
Defining the key intrahepatic gene networks in HCV infection driven by sex	302
Immunomodulation and entry inhibition: selgantolimod’s double punch against hepatitis B virus	287
Effect of long-term adherence on faecal immunochemical test positivity rate, positive predictive value and detection rate in organised population-based colorectal cancer screening	261
A mucus production programme promotes classical pancreatic ductal adenocarcinoma	248
Correction: P97 A patient information bundle outlining dietary advice in liver disease specific to the cost of living crisis improves patient care: ‘Looking after Your Liver for	240
Real-world evidence supports earlier treatment in HBeAg-positive but not HBeAg-negative chronic hepatitis B virus infection	235
Reassessing the prophylactic effect of clip closure to prevent delayed rebleeding after colorectal endoscopic submucosal dissection	231
Finding a mate for MLCK: improving the potential for therapeutic targeting of gut permeability	221
HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B	214
Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials	210
Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges	206
Refining intergenerational MASLD risk: are measurement and mediation shaping the signal?	200
Picking up microbial clues in early-onset colorectal cancer	182
COVID-19 and liver disease	170
Establishment of enterically transmitted hepatitis virus animal models using lipid nanoparticle-based full-length viral genome RNA delivery system	167
Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts	163
Where are we with gastric cancer screening in Europe in 2024?	153
Genetically proxied ketohexokinase function and risk of colorectal cancer: a Mendelian randomisation study	146
Current therapies and new developments in NASH	143
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation	139
Impact of margin thermal ablation after endoscopic mucosal resection of large (≥20 mm) non-pedunculated colonic polyps on long-term recurrence	139

Crohn’s disease and ulcerative colitis exhibit prediagnostic antibody signatures with shared and divergent changes towards disease onset	137
IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells	135
Growth rates and histopathological outcomes of small (6–9 mm) colorectal polyps based on CT colonography surveillance and endoscopic removal	131
Absence of a pancreatic microbiome in intraductal papillary mucinous neoplasm	128
Liquid biopsy to identify Barrett’s oesophagus, dysplasia and oesophageal adenocarcinoma: the EMERALD multicentre study	128
Rate of suitable cases for primary EUS-guided biliary drainage in distal malignant biliary obstruction	127
Third Asia-Pacific consensus recommendations on colorectal cancer screening and postpolypectomy surveillance	127
S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos	126
Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?	126
Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study	125
Need for standardised approaches to human microbiome research using the example of colorectal neoplasia research	125
Impact of climate change on vulnerable populations	120
MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression	118
Reflux conditions induce E-cadherin cleavage and EMT via APE1 redox function in oesophageal adenocarcinoma	117
Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates ZFP36L2 as a driver gene for pancreatic ductal adenocarcinoma	114
24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T H 17 pathogenicity and transdifferentiation	114
Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD	113
Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditio	112
Rare cause of obstructive jaundice	111
Quantifying artificial sweeteners and emulsifiers in Crohn’s disease and its relationship with disease activity: the ENIGMA study – a novel and targeted approach	111
Endoscopic mucosal and submucosal cutting for long benign oesophageal strictures	110
Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment	107
Definite benefits of GLP-1 receptor agonists: what is the risk of gastroparesis and lung aspiration?	106
Lumen-apposing metal stents versus double-pigtail plastic stents for infected necrotising pancreatitis: more doubts than answers	105
Perplexing case of abdominal pain with eosinophilia and fasciitis	104
Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model	102
Correction: Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	102
Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19	101
Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies	98
New entity of adult ultra-short coeliac disease: the first international cohort and case–control study	97
Steatosis severity and metabolic fingerprints after HCV eradication: toward an individualised approach to HCC surveillance after HCV cure	96
Selective decontamination of the digestive tract in critically ill children: fighting fire with fire or burning down the house?	94
Intron-mediated enhancement of SPINK1 expression for pancreatitis therapy	94
Limitations of Helicobacter pylori single-method testing: evidence from a cohort study	93
Tumour-intrinsic alterations and stromal matrix remodelling promote Wnt-niche independence during diffuse-type gastric cancer progression	91
Decoding HBV-specific adaptive immunity: from natural clearance to cure	90
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance	89
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities	88
Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling	86
Unveiling 8 years of duodenoscope contamination: insights from a retrospective analysis in a large tertiary care hospital	82
Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer	82
Association between appendectomy and Parkinson’s disease from the UK Biobank	78
Endoscopic stratification of gastric intestinal metaplasia: where are we, where do we want to go and how do we get there?	78
British Society of Gastroenterology guidelines on sedation in gastrointestinal endoscopy	78
SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination	77
Environmental and healthcare trade-offs between single-use and reusable gastroscopes	76
Treatment of type 2 diabetes with MASLD: new evidence for personalised medicine	76
Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?	75
Does the benefit of haemostatic powder differ by Forrest classification in non-variceal upper gastrointestinal bleeding?	74
Rethinking routine mapping biopsies in gastric intestinal metaplasia: justification for endoscopic stratification	74

Ebastine for the treatment of irritable bowel syndrome: old drug, new tricks?	74
GI highlights from the literature	74
Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity	73
Anticoagulation in colorectal ESD: implications for bleeding risk management	73
Correction: Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis	73
APCmosaicism, not always isolated: two first-degree relatives with apparently distinctAPCmosaicism	72
Correction: Revisiting the role of sphincterotomy in sphincter of oddi disorder: a critical appraisal of the RESPOnD study	72
SMYD2-mediated methylation of STAT1 protects against hepatic ischaemia/reperfusion injury by blocking JAK-STAT1 signalling pathways	71
Reply: Prevalence of serum HBsAg <100 IU/mL in inactive chronic hepatitis B	70
Postprandial symptoms in disorders of gut-brain interaction and their potential as a treatment target	70
A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis	70
Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis	70
Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8 + T cells	69
British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance	69
Offspring MASLD risk and the shared familial metabolic milieu: beyond intrauterine explanation	69
Gut microbe alleviates stress-related cancer metastasis by oleic acid degradation	68
Association between inflammatory bowel disease and Alzheimer’s disease: multivariable and bidirectional Mendelian randomisation analyses	67
Fasting-mimicking diet-enriched Bifidobacterium pseudolongum suppresses colorectal cancer by inducing memory CD8 +	67
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial	66
Gut-peritoneal-multisystem axis in endometriosis	65
Immunopathogenesis and environmental triggers in coeliac disease	65
Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity	65
Impact of age, comorbidities and relevant changes on surveillance strategy of intraductal papillary mucinous neoplasms: a competing risk analysis	64
Response letter to the editor	63
Understanding the malignant potential of gastric metaplasia of the oesophagus and its relevance to Barrett’s oesophagus surveillance: individual-level data analysis	63
Non-invasive assessment of MASH resolution	62
Clarifying the stopping rule and clinical value of AI-guided PEG titration for bowel preparation	61
Unravelling the obesity paradox in MASLD patients with extrahepatic cancer	60
MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer	60
NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression	59
GI highlights from the literature	59
Quest for HBV functional cure: what have we learnt from silencing RNAs?	58
Monocyte phenotypic liquid biopsy for NASH and liver fibrosis diagnosis: a new kid on the block	57
It takes two to TAM-go	57
Gastric emptying study before gastric peroral endoscopic myotomy (G-POEM): can intragastric meal distribution be a predictor of success?	57
GI highlights from the literature	56
Fatal intestinal disease: a case of recurrent lower gastrointestinal bleeding	56
A black liver	55
Crosstalk between liver sinusoidal endothelial cells and hepatocytes via IL-1α–IL1R1 axis exacerbates ischaemia/reperfusion injury in aged livers	55
In memoriam: Pelayo Correa, MD (1927–2025)	55
Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis	54
GI highlights from the literature	54
Correction: Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn’s Disease	54
Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients	54
Distinct microbial mediators link diet to inflammation in Crohn’s disease and ulcerative colitis	52
Prevalence of serum HBsAg <100 IU/mL in inactive chronic hepatitis B	52
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy	52
Abnormal gastrointestinal motility is a major factor in explaining symptoms and a potential therapeutic target in patients with disorders of gut–brain interaction	51
Submucosal steroid pre-injection strategy to prevent oesophageal stricture after circumferential endoscopic submucosal dissection	51
Nuclear Pirin promotes HCC by acting as a key inflammation-facilitating factor	51
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett’s oesophagus and stage I oesophageal adenocarcinoma	51
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions	50
Spatial dissection of tumour microenvironments in gastric cancers reveals the immunosuppressive crosstalk between CCL2+ fibroblasts and	50
Correction: PMO-29 Switching between infliximab biosimilars: experience from two inflammatory bowel disease centres	49
Risk of metachronous advanced neoplasia in patients with serrated lesions depending on follow-up schedule	49
Withdrawal of antitumour necrosis factor in patients with inflammatory bowel disease in remission: a randomised placebo-controlled clinical trial of GETECCU	48
Combining epigenetic modulation: the next step for HCC immunotherapy?	48
APC and P53 mutations synergise to create a therapeutic vulnerability to NOTUM inhibition in advanced colorectal cancer	47
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD	47
Targeting MLCK1 uncouples immune checkpoint inhibitor-induced colitis from antitumour immunity	47
Pericyte drives the formation of circulating tumour cell-neutrophil clusters to promote colorectal cancer metastasis	46
Fungi and cancer	46
The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines	45
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated st	45
Dominant-negative effect of lactase missense variants: hetero-complex assembly with the wild-type enzyme impairs intracellular trafficking and digestive function	45
Diagnostic dilemma: a patient with diarrhoea	44
Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis	44
GI highlights from the literature	43
ISG15–CREB1 ISGylation: a stellate cell brake in liver fibrosis	43
Interplay between diet, circulating indolepropionate concentrations and cardiometabolic health in US populations	42
SDC1 + CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers	42
Human enteric nervous system progenitor transplantation improves functional responses in Hirschsprung disease patient-derived tissue	42
Gut microbiota as non-invasive diagnostic and prognostic biomarkers for natural killer/T-cell lymphoma	42
The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells	42
Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition	42
Time-varying dynamics of hepatic steatosis and cardiometabolic risk: implications for posthepatitis C cure HCC risk	42
Impairment of Rab7-dependent STING degradation hampers HBV replication but accelerates disease progression in chronic hepatitis B comorbid with MASLD	41
Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy	41
IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis	41
Correction: Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway	41

Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989	41
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer	41
Assessment of the yearly carbon emission of a gastrointestinal endoscopy unit	41
NNMT enriches for AQP5 + cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma	40
Landscape of the gut mycobiome dynamics during pregnancy and its relationship with host metabolism and pregnancy health	40
Human milk oligosaccharide 2’-fucosyllactose protects against high-fat diet-induced obesity by changing intestinal mucus production, composition and degradation linked to changes in gut microbiota and	40
Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2	40
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis	40
Tailoring treatment to the circumstance: reasoning behind metal versus plastic drainage of pancreatic collections	39
Is HBx protein the X factor in the pathogenesis of IBD?	39
GI snapshot: arrhythmia, dysphagia and weight loss in a 71-year-old man	38
GI highlights from the literature	38
Variceal band ligation and carvedilol: together forever, or not?	38
Zinc-dependent post-transcriptional control of hepatocyte fate in and regeneration of alcohol-associated liver disease	37
Eosinophils: a novel therapeutic target to promote liver regeneration in acute liver injury?	37
Is the significant risk of perioperative complications associated with radical surgery following non-curative endoscopic submucosal dissection for early colorectal cancer still acceptable?	37
Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study	37
Alcohol exhibits contrasting effects on CD8 + T cells in the gut and liver in alcohol-associated liver disease	37
Correction: O4 Acceptability and feasibility of a multimodal early detection pilot study for liver disease in high risk groups: “Alright My Liver?”	36
Real-world treatment patterns in microscopic colitis: a nationwide study from Sweden	36
Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohn’s disease	36
Correction: Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)	36
SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis	36
Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro	35
Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial	35
Vessel and tissue recognition during third-space endoscopy using a deep learning algorithm	35
Basal levels of microbiota-driven subclinical inflammation are associated with anastomotic leak in patients with colorectal cancer	35
Gut microbiome and dietary fibre intake strongly associate with IgG function and maturation following SARS-CoV-2 mRNA vaccination	35
Endocytoscopy with automated multispectral intestinal barrier pathology imaging for assessment of deep healing to predict outcomes in ulcerative colitis	35
Artificial intelligence applied to ‘omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment	34
Sex-based differences in prescribed medications, surgical procedures and disease-related complications in IBD	34
Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier fami	34
Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications	34
Correction: Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma	34
Nuclear translocation of plasma membrane protein ADCY7 potentiates T cell-mediated antitumour immunity in HCC	34
Organoids in gastrointestinal diseases: from experimental models to clinical translation	33
Trends and cross-country inequality in the incidence of GI cancers among the working-age population from 1990 to 2021: a Global Burden of Disease 2021 analysis	33
PDE5A + cancer-associated fibroblasts enhance immune suppression in gastric cancer	33
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade	33
Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?	33
Rise of precision medicine: can it deliver on its promise in IBD?	32
CD48 is a novel immune checkpoint on tumour‐associated macrophages in hepatocellular carcinoma	32
Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists	32
Precancerous nature of intestinal metaplasia with increased chance of conversion and accelerated DNA methylation	32
Universal ESD for Barrett’s neoplasia: the T1b ‘“limbo’” and risk of overtreatment	32
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis	32
Alterations to the duodenal microbiota are linked to gastric emptying and symptoms in functional dyspepsia	32
Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy	32
HBV integrations reshaping genomic structures promote hepatocellular carcinoma	32
DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer	31
British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma	31
Correction: O11 Utilising peer support workers in hepatitis C screening in emergency departments: a pilot study	31
Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study	31
CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases	31
Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance	31
Cold versus hot snare endoscopic mucosal resection for large (≥15 mm) flat non-pedunculated colorectal polyps: a randomised controlled trial	31
Correction: Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19	31
Correction: British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025	30
Global prevalence of self-reported non-coeliac gluten and wheat sensitivity: a systematic review and meta-analysis	30
Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives	30
Germline mutations and pancreatic cancer risk in chronic pancreatitis	30
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease	30
Genetic and transcriptomic landscape of colonic diverticulosis	30
Reconsidering statins in MASLD: beyond cardiovascular protection to multisystem benefit	30
Patient selection for urgent endoscopic retrograde cholangio-pancreatography by endoscopic ultrasound in predicted severe acute biliary pancreatitis (APEC-2): a multicentre prospective study	30
Response to: ‘Differentiating gastroparesis from functional dyspepsia is no longer sufficient’ by O’Grady et al	29
More than meets the eye: a strange cause of bowel obstruction and perforation	29
eCura and W-eCura: different scores, different populations, same goal	29
Response to ‘Biliary sludge and microlithiasis: are we covering the full spectrum of lithogenic biliary disorders?’	29
Presenilins: the hidden guardians of gut health in Alzheimer’s disease	29
Ferritin—a promising biomarker in MASLD	29
Purified oat protein can trigger acute symptoms linked to immune activation in coeliac disease patients but not histological deterioration	28
Purastat post-EMR: unresolved questions from the PURPLE trial	28
Response to the letter to the editor ‘revisiting lipid dysregulation in colorectal cancer: critical appraisal of pro-inflammatory bias and therapeutic implications’	28
Reply to Newmanet al‘Response to epidemiology of inflammatory bowel disease in men with high-risk homosexual activity’	28
Unusual cause of abdominal pain	28
Is the biogeography of the mucosa-associated microbiota a key factor affecting primary sclerosing cholangitis disease course and treatment?	28
Novel myo -inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis,	27
An unusual cause of oesophageal stricture	27
Porcine-derived pancreatic enzyme replacement therapy: a cause of hepatitis E virus transmission?	27
Congenital sucrase-isomaltase mutations worsen IBS-linked V15F dysfunction and trafficking	27
Hepatocyte guardian: A20 restrains ferroptosis in autoimmune hepatitis	27
Gnotobiotic mice housing conditions critically influence the phenotype associated with transfer of faecal microbiota in a context of obesity	27
Performance of the China-CLIF framework in acute-on-chronic liver failure: a multicohort study across all aetiologies	27
CD177+ neutrophils: new drivers of liver regeneration	27
Cutting waste in endoscopy: the roles of professional practice and staffing levels	27
Accuracy of measuring colorectal polyp size in pathology: a prospective study	26
DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma	26
Key metabolomic alterations are associated with ulcerative colitis disease state and activity: a validation analysis	26
Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn’s disease	26
CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma	26
Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPG	26
Adherent-invasive Escherichia coli in Crohn’s disease: the 25th anniversary	26
Stressed hepatocyte sustains alcohol-associated hepatitis progression by producing leukocyte cell-derived chemotaxin 2	26
Smoking affects gut immune system of patients with inflammatory bowel diseases by modulating metabolomic profiles and mucosal microbiota	26